Philips CPAP Recall Lawsuit

Philips Respironics has issued a recall for millions of its DreamStation CPAP sleep apnea and other breathing machines due to an increased risk of people developing severe side effects from using these products. The devices are being recalled over concerns that their foam liners may disintegrate or offgas, potentially causing users to inhale contaminants and/or toxic chemicals. Anyone who has experienced severe side effects after using a Phillips Bi-Level Positive Airway Pressure (Bi-Level PAP), Continuous Positive Airway Pressure (CPAP), or mechanical ventilator device may be eligible for compensation by filing a Philips CPAP lawsuit.

Philips Recall Lawsuits
Philips may soon face several lawsuits filed by people who were diagnosed with cancer or other injuries (listed below) after using a Philips Sleep & Respiratory Care CPAP, Bi-level PAP, or a mechanical ventilator.

Philips has provided a “Sleep and Respiratory Care update: Clinical information for physicians.” It lists the following possible Injuries Philips device users could suffer from inhaling or ingesting foam particles:

Potential risks of degraded foam exposure include:
o Headache
o Inflammatory response
o Irritation (skin, eyes, and respiratory tract)
o Asthma
o Adverse effects to other organs (e.g. kidneys and liver)
o Toxic and carcinogenic effects (cancers)

Potential Risks from Volatile Organic Compounds (VOCs) from degraded foam exposure include:
o Irritation (skin, eyes, nose, respiratory tract)
o Headache/dizziness
o Hypersensitivity
o Nausea/vomiting
o Toxic and carcinogenic effects (cancer)

Philips CPAP Recall Update: 3-4 Million Devices Recalled
On April 26, 2021, Philips provided an important update regarding its efforts to address issues the company identified in several of its Sleep and Respiratory Care products. Further, Philips ceased all sales of its DreamStation 1 CPAP products in the US, then updated that recall last month, in June 2021. Because the recall is considered voluntary, it will likely be considered a Class II FDA recall. It is currently listed as a safety notification.

The recall involves millions of Philips’ sleep apnea and ventilator machines, most of which are of the DreamStation, first-generation production line and are within the 5-year service life. Philips issued the recall for machines that contain a sound-abatement foam comprised of polyester-based polyurethane which may degrade to release particles and chemicals that can be inhaled. Philips estimates that up to four (4) million devices may be affected in the U.S. market.

Recalled Philips Devices Include All of the following devices manufactured before April 26, 2021:

CPAP and BiLevel PAP

Continuous Ventilator, Non-life Supporting
• DreamStation ASV
• DreamStation ST, AVAPS
• SystemOne ASV4
• C Series ASV, S/T, AVAPS
• OmniLab Advanced Plus In-Lab Titration Device

Non-continuous Ventilator
• SystemOne Q series
• DreamStation CPAP, Auto CPAP, BiPAP
• DreamStation Go CPAP, APAP
• Dorma 400, 500 CPAP

Continuous Ventilator, Minimum Ventilatory Support, Facility Use
• E30 (Under Emergency Use Authorization)

Mechanical Ventilators

Continuous Ventilator
• Trilogy 100Ventilator
• Trilogy 200Ventilator
• Garbin Plus, Aeris, LifeVent Ventilator

Continuous Ventilator, Minimum Ventilatory Support, Facility Use
• A-Series BiPAP V30 AutoVentilator

Sound-reducing Foam Liner suspected
Risks of severe adverse side effects, including cancer, appear to be related to the polyester-based polyurethane (PE-PUR) foam used as a sound-abatement component in certain models of the devices. PE-PUR foam may degrade into particles that could enter into the device air pathway and be inhaled or ingested by the user. The foam may also be prone to “offgas” chemicals that could be toxic. Degradation and chemical offgassing problems could be exacerbated by unapproved cleaning methods that include high heat, high humidity, and ozone cleaning environments.

Canadian government officials have noted: “[R]esults of testing performed by Philips indicate the PE-PUR sound abatement foam used in these devices may emit certain chemicals. Our investigation to date indicates that this emission occurs during initial operation and may possibly continue throughout the device’s useful life.”

Philips Respironics notes that the absence of visible particles does not mean that foam breakdown has not already begun. Lab analysis of the degraded foam reveals the presence of potentially harmful chemicals that include:

• Toluene Diamine
• Toluene Diisocyanate
• Diethylene glycol

Lab testing performed for and by Philips also identified the presence of VOCs which may be emitted from the sound abatement foam component of the affected device(s). VOCs are emitted as gases from the foam included in the CPAP, Bi-Level PAP, and mechanical ventilator devices. Such gases may have short- and long-term adverse health effects. Philips’ own lab testing identified two compounds of concern that may be emitted from the foam that are outside of safety thresholds: Dimethyl Diazine and Phenol, 2,6-bis (1,1-dimethylethyl)-4-(1-methylpropyl).

Philips Breathing Machines Symptoms of Exposure
Though actual complaints have been few to date, some users have reported black debris collecting in their breathing tubes. The potential degradation of PE-PUR foam may lead to inhalation of degraded products and toxic chemicals from initial use of the Philips devices. This problem could increase the chance of severe adverse side effects and might also increase cancer risk.

Symptoms of exposure may include:
• Coughing
• Headache
• Throat irritation
• Lung inflammation
• Nausea and vomiting
• Sinus infections
• Carcinogenic effects
• And more

Recalls and Countries Affected
• United States
• Canada
• Australia

About Philips Group
Philips is one of the largest makers of sleep apnea machines and ventilators in the world. An estimated 3-4 million devices are targeted in this recall. Philips Group company spokesman Steve Klink said that approximately 80% of the affected devices in the recall were machines used to help people with sleep apnea, known as Continuous Positive Airway Pressure (CPAP) machines. All users of those machines were advised to halt usage. About two-thirds of Philips CPAP machine sales occur in the United States. The other 20% of affected devices were mechanical ventilators.

Philips’ 2020 Annual Report indicates Philips Group generated approximately EUR 19.5 billion ($23.14 billion) in total sales. Philips’ “Connected Care” business segment (which contains Philips’ Sleep & Respiratory Care Products) comprised roughly 28% of total sales – approximately $6.6 billion US dollars or EUR 5.564 billion. Philips Group CEO Frans van Houten announced that the company has set aside EUR 500 million ($606 million) to date for dealing with this recall. The company stated in its Q1 Earnings Call that this amount does not account for potential litigation that may ensue.

Philips CPAP Injury Lawsuit
A Philips CPAP, BiPAP and ventilator user who has been injured after using one of the recalled devices may be eligible for compensation for related injuries. Anyone who has suffered severe adverse side effects or who has been diagnosed with cancer after using a Philips Bi-Level Positive Airway Pressure (Bi-Level PAP), Continuous Positive Airway Pressure (CPAP) or mechanical ventilator device can contact Matthews & Associates immediately for a free case evaluation.